| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 靶点及因子类蛋白(元) | 41,846,420.14 | 64,593,303.09 | 29,129,077.19 | 59,606,075.08 | 27,215,914.45 |
| 技术服务(元) | - | 15,848,872.88 | - | - | 5,338,621.13 |
| 酶及试剂(元) | 18,474,457.18 | 41,719,193.17 | 19,769,434.84 | 70,001,075.46 | 38,269,251.20 |
| 重组抗体(元) | 1,928,029.50 | 5,241,486.54 | 3,086,286.36 | 7,618,123.50 | 3,823,272.84 |
| CRO服务(元) | 8,555,182.02 | - | 7,620,771.42 | 15,824,568.96 | - |
| 营业成本(元) | |||||
| 靶点及因子类蛋白(元) | 9,452,918.98 | 18,305,939.13 | 8,608,361.97 | 13,065,517.78 | - |
| 技术服务(元) | - | 12,492,289.84 | - | - | - |
| 酶及试剂(元) | 6,483,222.66 | 15,895,037.38 | 7,640,946.91 | 9,980,635.67 | - |
| 重组抗体(元) | 344,766.55 | 1,200,478.36 | 480,817.96 | 1,141,415.23 | - |
| CRO服务(元) | 8,155,952.53 | - | 5,101,127.77 | 13,014,221.16 | - |
| 毛利(元) | |||||
| 靶点及因子类蛋白(元) | 32,393,501.16 | 46,287,363.96 | 20,520,715.22 | 46,540,557.30 | - |
| 技术服务(元) | - | 3,356,583.04 | - | - | - |
| 酶及试剂(元) | 11,991,234.52 | 25,824,155.79 | 12,128,487.93 | 60,020,439.79 | - |
| 重组抗体(元) | 1,583,262.95 | 4,041,008.18 | 2,605,468.40 | 6,476,708.27 | - |
| CRO服务(元) | 399,229.49 | - | 2,519,643.65 | 2,810,347.80 | - |
| 毛利率(%) | |||||
| 靶点及因子类蛋白(%) | 77.41 | 71.66 | 70.45 | 78.08 | - |
| 技术服务(%) | - | 21.18 | - | - | - |
| 酶及试剂(%) | 64.91 | 61.90 | 61.35 | 85.74 | - |
| 重组抗体(%) | 82.12 | 77.10 | 84.42 | 85.02 | - |
| CRO服务(%) | 4.67 | - | 33.06 | 17.76 | - |
| 收入构成(%) | |||||
| 靶点及因子类蛋白(%) | 59.10 | 50.70 | 48.87 | 38.95 | 36.46 |
| 技术服务(%) | - | 12.44 | - | - | 7.15 |
| 酶及试剂(%) | 26.09 | 32.75 | 33.17 | 45.74 | 51.27 |
| 重组抗体(%) | 2.72 | 4.11 | 5.18 | 4.98 | 5.12 |
| CRO服务(%) | 12.08 | - | 12.79 | 10.34 | - |
| 毛利构成(%) | |||||
| 靶点及因子类蛋白(%) | 69.86 | 58.22 | 54.32 | 40.17 | - |
| 技术服务(%) | - | 4.22 | - | - | - |
| 酶及试剂(%) | 25.86 | 32.48 | 32.11 | 51.81 | - |
| 重组抗体(%) | 3.41 | 5.08 | 6.90 | 5.59 | - |
| CRO服务(%) | 0.86 | - | 6.67 | 2.43 | - |